TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Genetic Signatures Ltd. ( (AU:GSS) ) is now available.
Genetic Signatures Ltd has announced a strategic partnership with Tecan and Repado to develop a fully automated, scalable diagnostic platform for infectious disease testing. This collaboration aims to enhance laboratory efficiency and compliance by integrating Tecan’s automation technology, Repado’s regulatory-compliant software, and Genetic Signatures’ assay portfolio. The initiative is expected to significantly improve testing processes and regulatory alignment, with early access planned for select global labs.
The most recent analyst rating on (AU:GSS) stock is a Buy with a A$1.10 price target. To see the full list of analyst forecasts on Genetic Signatures Ltd. stock, see the AU:GSS Stock Forecast page.
More about Genetic Signatures Ltd.
Genetic Signatures Ltd is a global molecular diagnostics company specializing in infectious disease assays. The company focuses on providing innovative diagnostic solutions for syndromic testing laboratories, with a portfolio that includes panels for respiratory, gastrointestinal, and sexually transmitted infections.
Average Trading Volume: 107,726
Technical Sentiment Signal: Sell
Current Market Cap: A$89.72M
See more insights into GSS stock on TipRanks’ Stock Analysis page.